- Mylan subsidiary gets approval for HIV generic under PEPFAR
- Adherence among chronic disease patients can lead to big savings
- Walgreens puts its money where its mouth is with World AIDS Day campaign
- Moving PSE to Rx-only in Mo. lacks fiscal sense
- Walgreens allies with HHS to launch free flu shot outreach to disadvantaged
PITTSBURGH — The World Health Organization has approved three generic second-line treatments for HIV made by Mylan, the drug maker said Tuesday. The drugs will be delivered to people in developing countries living with HIV and AIDS.
Subsidiary Mylan Labs won approval for atazanavir capsules in the 300-mg strength and ritonavir tablets in the 100-mg strength with tenofovir disoproxil fumarate and lamivudine tablets in the 300-mg/300-mg strength; a fixed-dose combination of atazanavir sulfate and ritonavir tablets in the 300-mg/100-mg strength; and a fixed-dose combination tablet of abacavir sulfate, lamivudine and zidovudine in the 300-mg/150-mg/300-mg strength.
Atazanavir, ritonavir, tenofovir disoproxil fumarate and lamivudine are generic versions of Bristol-Myers Squibb's Reyataz, Abbott Labs' Norvir, Gilead Sciences Viread and GlaxoSmithKline's Epivir, respectively.